Outcome after splenic vein thrombosis in the pancreas allograft.
The outcome and management of isolated splenic vein thrombosis in the pancreas transplant is unknown. We retrospectively reviewed the records of 76 simultaneous pancreas-kidney transplantations (SPK) and 56 solitary pancreas transplantations (SPT) performed at the University of Maryland from January 1995 to December 1996. A total of 24 patients were identified (9 SPK and 15 SPT recipients). All were systemically anticoagulated for a period of 6-8 weeks after diagnosis. In the SPK thrombosis group, anticoagulation resulted in 1-year graft survival that was equivalent to that of SPK controls (86.1% vs. 95.3%). In contrast, in SPT, thrombosis and subsequent anticoagulation were associated with decreased graft survival compared with SPT controls (26.8% vs. 78.3%; P<0.01). Although the outcome of splenic vein thrombosis in the absence of anticoagulation is unknown, these data suggest that (1) in SPK, anticoagulation for splenic vein thrombosis maintains graft survival, and (2) in SPT, anticoagulation does not alter the ultimate progression of splenic vein thrombosis to complete graft thrombosis.
Kuo
P C
PC
Department of Surgery, University of Maryland Medical System, Baltimore 21201, USA. pkuo@surgery1.ab.umd.edu
Wong
J
J
Schweitzer
E J
EJ
Johnson
L B
LB
Lim
J W
JW
Bartlett
S T
ST
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival; D006785:Hospitals, University; D006801:Humans; D016030:Kidney Transplantation; D008396:Maryland; D016035:Pancreas Transplantation; D011183:Postoperative Complications; D015995:Prevalence; D012189:Retrospective Studies; D013162:Splenic Vein; D013927:Thrombosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000925:Anticoagulants